Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

NCT00002043 is registered in ClinicalTrials.gov with Jacobus Pharmaceutical as lead sponsor.

NCT NCT00002043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)
Lead sponsor
Jacobus Pharmaceutical
Phase
Not applicable
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, pneumonia, pneumocystis carinii